Menu
Search
|

Menu

Close
X

Ovid Therapeutics Inc OVID.OQ (NASDAQ Stock Exchange Global Select Market)

10.73 USD
-- (--)
As of Jul 20
chart
Previous Close 10.73
Open --
Volume --
3m Avg Volume 23,670
Today’s High --
Today’s Low --
52 Week High 12.36
52 Week Low 5.28
Shares Outstanding (mil) 24.62
Market Capitalization (mil) 260.52
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.536
FY17
-2.395
FY16
-0.911
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.34
Price to Sales (TTM)
vs sector
--
8.11
Price to Book (MRQ)
vs sector
3.66
4.23
Price to Cash Flow (TTM)
vs sector
--
22.22
Total Debt to Equity (MRQ)
vs sector
0.00
17.18
LT Debt to Equity (MRQ)
vs sector
0.00
13.08
Return on Investment (TTM)
vs sector
-59.79
13.18
Return on Equity (TTM)
vs sector
-59.79
15.09

EXECUTIVE LEADERSHIP

Jeremy Levin
Chairman of the Board, Chief Executive Officer, Since 2015
Salary: $500,000.00
Bonus: --
Matthew During
President, Chief Scientific Officer, Director, Since 2015
Salary: --
Bonus: --
Yaron Werber
Chief Business and Financial Officer, Secretary, Since 2016
Salary: --
Bonus: --
Dirk Haasner
Senior Vice President - Global Regulatory Affairs, Since 2016
Salary: $294,952.00
Bonus: --
Timothy Daly
Vice President - Finance, Corporate Controller, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1460 Broadway Ste 15044
NEW YORK   NY   10036-7329

Phone: +1646.6617661

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.

SPONSORED STORIES